Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
The company said at a conference that Orkambi refills have lagged during the third quarter.
The biotechnology sector made sizeable gains on Monday amid acquisition news.
After Pfizer's $14 billion proposed acquisition of Medivation, these biotech stocks could emerge as winners, if history is any guide.
CNBC's Meg Tirrell reports on the action in the IBB biotech ETF after Pfizer announced it was buying Medivation and what some other big M&A deals could be coming down the line. The "Fast Money" traders weigh in.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
The hunt for yield has increased valuations for pharma stocks above their biotech counterparts, a rare feat that may present a buying opportunity.
Check out the companies making headlines after the bell on Monday.
In a world mired in sluggish growth, those looking to buy attractively valued growth stocks may need to get creative. Asset manager Jason Donville has some ideas.
Michael Yee, RBC analyst, shares his views on the biotech breakout. The "Fast Money" traders weigh in.
Jim Cramer highlights one group that was a clear winner of the first half of 2016.
Sam Isaly, OrbiMed Advisors founder, discusses health care industry stock picks.
As the first quarter comes to a close, one sector notably stands out in the negative column: biotech.
RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at stocks with analyst recommendations, including Vertex Pharmaceuticals, GoPro and Tesla.
Brian Abrahams of Jefferies, who has one of the best track records on Wall Street, just upgraded a biotech stock.
RBC Capital Markets analyst Michael Yee says there are three biotech stocks to own next year no matter how the sector performs in 2016.
Personalized medicine is more costly than traditional treatment, which worries insurers. But these drugs can improve outcomes for patients.
Jim Cramer provides his opinion on caller favorite stocks, including this telecommunications play.
Some of the names on the move ahead of the open.